Characterization of Poliovirus Variants Selected for Resistance to the Antiviral Compound V-073
Open Access
- 1 November 2012
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (11), 5568-5574
- https://doi.org/10.1128/aac.00539-12
Abstract
V-073, a small-molecule capsid inhibitor originally developed for nonpolio enterovirus indications is considerably more potent against polioviruses. All poliovirus isolates tested to date ( n = 45), including wild, vaccine, vaccine-derived, and laboratory strains, are susceptible to the antiviral capsid inhibitor V-073. We grew poliovirus in the presence of V-073 to allow for the identification of variants with reduced susceptibility to the drug. Sequence analysis of 160 independent resistant variants (80 isolates of poliovirus type 1, 40 isolates each of types 2 and 3) established that V-073 resistance involved a single amino acid change in either of two virus capsid proteins, VP1 (67 of 160 [42%]) or VP3 (93 of 160 [58%]). In resistant variants with a VP1 change, the majority (53 of 67 [79%]) exhibited a substitution of isoleucine at position 194 (equivalent position 192 in type 3) with either methionine or phenylalanine. Of those with a VP3 change, alanine at position 24 was replaced with valine in all variants ( n = 93). The resistance phenotype was relatively stable upon passage of viruses in cell culture in the absence of drug. Single-step growth studies showed no substantial differences between drug-resistant variants and the virus stocks from which they were derived, while the resistant viruses were generally more thermally labile than the corresponding drug-susceptible parental viruses. These studies provide a foundation from which to build a greater understanding of resistance to antiviral compound V-073.This publication has 13 references indexed in Scilit:
- Immunological and Pathogenic Properties of Poliovirus Variants Selected for Resistance to Antiviral Drug V-073Antiviral Therapy, 2011
- SwissParam: A fast force field generation tool for small organic moleculesJournal of Computational Chemistry, 2011
- In Vitro Antiviral Activity of V-073 against PoliovirusesAntimicrobial Agents and Chemotherapy, 2009
- A case for developing antiviral drugs against polioAntiviral Research, 2008
- Scalable molecular dynamics with NAMDJournal of Computational Chemistry, 2005
- Vaccine Policy Changes and Epidemiology of Poliomyelitis in the United StatesJAMA, 2004
- SWISS-MODEL: an automated protein homology-modeling serverNucleic Acids Research, 2003
- Attenuated Virulence of Pleconaril‐Resistant Coxsackievirus B3 VariantsThe Journal of Infectious Diseases, 1999
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996
- Use of drug-resistance mutants to identify functional regions in picornavirus capsid proteinsPublished by Springer Science and Business Media LLC ,1994